Imago BioSciences, Inc. (IMGO) News
Filter IMGO News Items
IMGO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IMGO News Highlights
- IMGO's 30 day story count now stands at 4.
- Over the past 8 days, the trend for IMGO's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
Latest IMGO News From Around the Web
Below are the latest news stories about IMAGO BIOSCIENCES INC that investors may wish to consider to help them evaluate IMGO as an investment opportunity.
5 Top Pharma Stocks of 2022 to Buy for the Long HaulThe biggest drug company blockbusters bring in billions of dollars, which is one of the reasons to consider these top Pharma stocks. |
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in MyelofibrosisREDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that the first participant has been dosed in an investigator-sponsored Phase 2 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination |
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022- 100% of patients treated with bomedemstat for ≥24 weeks (n=62 as of October 18, 2022) achieved a platelet count in the normal range with a median time to first normal platelet count of 10 weeks — - Of 28 patients treated with bomedemstat for 48 weeks, 89% (25/28) achieved a durable (≥12 weeks) platelet count in the normal range by week 48 - - 67% (20/30) of patients treated with bomedemstat experienced a decrease in mutant allele frequencies, including JAK2 and CALR – - All 5 patients with bas |
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022- As of the data cutoff of 18 October 2022, bomedemstat demonstrated spleen volume reduction in 66% (33/50) of patients and reduction in total symptom score in 65% (17/26) of patients at 24 weeks - - No patients in this Phase 2 study of bomedemstat in advanced myelofibrosis have progressed to acute myeloid leukemia while on treatment - - The Phase 2 study of bomedemstat in advanced myelofibrosis is fully enrolled, with an investigator-sponsored Phase 2 combination study of bomedemstat and ruxoli |
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.RAHWAY, N.J., December 12, 2022--Merck Begins Tender Offer to Acquire Imago BioSciences, Inc. |
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid LeukemiaREDWOOD CITY, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that the first participant has been dosed in an investigator-sponsored Phase 1 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with venetoclax ( |
3 Dow Stocks to Take Seriously in 2023The top Dow stocks for 2023 are all big free cash flow generators that ought to be able to cope with whatever next year brings. |
Horizon Therapeutics Fields Takeover Interest From Pharma GiantsThe drugmaker recently had a market value almost $18 billion as big pharmaceutical companies rely on acquisitions to expand sales. |
Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New IndicationMerck (MRK) offers to buy Imago Biosciences (IMGO). The European Commission approves AbbVie's (ABBV) immunology medicine, Skyrizi for Crohn's disease. |
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN) and Imago BioSciences (IMGO)Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arvinas Holding Company (ARVN – Research Report) and Imago BioSciences (IMGO – Research Report). Arvinas Holding Company (ARVN) H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Arvinas Holding Company today and set a price target of $90.00. The company's shares closed last Monday at $43.08, close to its 52-week low of $34.90. According to TipRanks. |